Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,568,182
  • Shares Outstanding, K 101,830
  • Annual Sales, $ 88,640 K
  • Annual Income, $ -227,280 K
  • 60-Month Beta 1.39
  • Price/Sales 17.49
  • Price/Cash Flow N/A
  • Price/Book 7.11
Trade HRTX with:

Options Overview

Details
  • Implied Volatility 91.53%
  • Historical Volatility 38.96%
  • IV Percentile 75%
  • IV Rank 41.05%
  • IV High 169.70% on 06/26/20
  • IV Low 37.09% on 09/18/20
  • Put/Call Vol Ratio 0.33
  • Today's Volume 232
  • Volume Avg (30-Day) 676
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 17,387
  • Open Int (30-Day) 24,654

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.57
  • Number of Estimates 5
  • High Estimate -0.53
  • Low Estimate -0.61
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +6.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.96 +21.68%
on 06/01/21
15.78 -0.06%
on 06/14/21
+1.92 (+13.86%)
since 05/14/21
3-Month
12.96 +21.68%
on 06/01/21
18.99 -16.96%
on 04/28/21
-1.17 (-6.91%)
since 03/12/21
52-Week
12.52 +25.96%
on 06/29/20
22.40 -29.60%
on 12/28/20
-2.98 (-15.89%)
since 06/12/20

Most Recent Stories

More News
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 110.48 (+0.52%)
ACRX : 1.5400 (unch)
ACOR : 4.21 (+9.35%)
AXSM : 67.52 (+1.70%)
BAYRY : 16.2200 (-0.25%)
BDRFF : 119.3501 (+0.97%)
BDSI : 3.63 (-0.55%)
BMY : 67.29 (-0.07%)
COLL : 22.99 (-1.63%)
DEPO : 7.30 (+1.67%)
DRRX : 1.7100 (-2.29%)
EGLT : 0.0315 (-63.37%)
LLY : 226.10 (+0.90%)
FLXN : 8.91 (-4.19%)
GLPG : 79.02 (-0.40%)
HRTX : 15.77 (+2.40%)
KMPH : 14.40 (-1.50%)
MRK : 75.45 (-1.08%)
MESO : 8.42 (-1.29%)
NKTR : 17.68 (+0.40%)
NVS : 93.59 (+0.97%)
ORXOY : 4.8600 (-11.60%)
PFE : 39.63 (-1.30%)
REGN : 528.75 (+0.61%)
VRX.TO : 30.80 (-3.33%)
Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 15.77 (+2.40%)
Heron Therapeutics Announces $150 Million Convertible Debt Financing

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron") today announced that it has sold of senior unsecured convertible promissory notes (the "Notes") in a private placement transaction....

HRTX : 15.77 (+2.40%)
First Week of July 16th Options Trading For Heron Therapeutics (HRTX)

Investors in Heron Therapeutics Inc saw new options begin trading this week, for the July 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRTX options chain...

HRTX : 15.77 (+2.40%)
Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HRTX, CSPR, EOLS, XERS, and ATRA.

ATRA : 14.66 (+1.81%)
EOLS : 12.38 (+0.41%)
XERS : 3.93 (-0.51%)
HRTX : 15.77 (+2.40%)
CSPR : 9.72 (-0.10%)
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 15.77 (+2.40%)
Heron Therapeutics (HRTX) Reports Q1 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -1.75% and -25.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

HRTX : 15.77 (+2.40%)
Heron Therapeutics: Q1 Earnings Snapshot

SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Monday reported a loss of $52.6 million in its first quarter.

HRTX : 15.77 (+2.40%)
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 15.77 (+2.40%)
Interesting HRTX Put And Call Options For December 17th

Investors in Heron Therapeutics Inc saw new options become available this week, for the December 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay,...

HRTX : 15.77 (+2.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

3rd Resistance Point 16.32
2nd Resistance Point 16.05
1st Resistance Point 15.91
Last Price 15.77
1st Support Level 15.50
2nd Support Level 15.23
3rd Support Level 15.09

See More

52-Week High 22.40
Fibonacci 61.8% 18.63
Fibonacci 50% 17.46
Fibonacci 38.2% 16.29
Last Price 15.77
52-Week Low 12.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar